Quanterix Corporation (QTRX)

NASDAQ: QTRX · Real-Time Price · USD
2.880
-0.030 (-1.03%)
At close: May 13, 2026, 4:00 PM EDT
2.890
+0.010 (0.35%)
After-hours: May 13, 2026, 6:24 PM EDT
Market Cap135.67M -42.2%
Revenue (ttm)144.98M +6.8%
Net Income-104.19M
EPS-2.33
Shares Out 47.11M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,339,305
Open2.915
Previous Close2.910
Day's Range2.810 - 2.985
52-Week Range2.560 - 8.770
Beta1.15
AnalystsHold
Price Target4.00 (+38.89%)
Earnings DateMay 6, 2026

About QTRX

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include assays include all components required to run enzyme-based immunoassay, s... [Read more]

Sector Healthcare
IPO Date Dec 7, 2017
Employees 450
Stock Exchange NASDAQ
Ticker Symbol QTRX
Full Company Profile

Financial Performance

In 2025, Quanterix's revenue was $138.90 million, an increase of 1.07% compared to the previous year's $137.42 million. Losses were -$107.15 million, 178.1% more than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for QTRX stock is "Hold." The 12-month stock price target is $4.0, which is an increase of 38.89% from the latest price.

Price Target
$4.0
(38.89% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Quanterix announces CFO transition

Quanterix (QTRX) “announced that Vandana Sriram, its CFO will depart the Company. A search for her successor is ongoing, and Ms. Sriram will continue as CFO through June 15, 2026,…

1 day ago - TheFly

Quanterix Announces Planned Transition of Chief Financial Officer

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that V...

1 day ago - Business Wire

Quanterix price target lowered to $4 from $7 at TD Cowen

TD Cowen lowered the firm’s price target on Quanterix (QTRX) to $4 from $7 and keeps a Hold rating on the shares. The firm said 1Q was largely in line…

6 days ago - TheFly

Lucent Diagnostics announces collaboration with Tempus AI

Lucent Diagnostics, a brand of Quanterix Corporation (QTRX), announced a collaboration with Tempus AI (TEM) to broaden access to a novel blood-based biomarker panel designed to improve detection accur...

Other symbols: TEM
7 days ago - TheFly

Quanterix reports Q1 EPS (37c), consensus (62c)

Reports Q1 revenue $36.4M, consensus $36.84M. The company said, “”We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we…

7 days ago - TheFly

Quanterix affirms 2026 revenue outlook $169M-$174M

The company said, “Quanterix (QTRX) is reaffirming its guidance for 2026. The Company expects revenues of $169 to $174 million, which assumes no underlying improvement in the academic or pharmaceutica...

7 days ago - TheFly

Quanterix Earnings Call Transcript: Q1 2026

Q1 2026 revenue grew 20% year-over-year to $36.4 million, with strong diagnostics partner growth but declines in core segments. Strategic investments in commercial effectiveness and diagnostics are expected to drive a stronger second half, with cash flow breakeven targeted by year-end.

7 days ago - Transcripts

Quanterix Releases Financial Results for the First Quarter of 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financ...

7 days ago - Business Wire

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading ...

Other symbols: TEM
7 days ago - Business Wire

Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...

19 days ago - Business Wire

Quanterix price target lowered to $4 from $8 at Canaccord

Canaccord lowered the firm’s price target on Quanterix (QTRX) to $4 from $8 and keeps a Hold rating on the shares. The firm updated its model ahead of Q1 results.

23 days ago - TheFly

Quanterix, PreludeDX highlights AidaBREAST multi-omic assay

PreludeDx and Quanterix (QTRX) Corporation highlighted that AidaBREAST, a multi-omic assay made to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breas...

26 days ago - TheFly

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

LAGUNA HILLS, Calif. & BILLERICA, Mass.--(BUSINESS WIRE)--PreludeDx® and Quanterix Corporation (Nasdaq: QTRX) today highlighted that AidaBREAST™, the first multi-omic assay to predict both locoregiona...

26 days ago - Business Wire

Quanterix debuts Content Innovation Engine at AACR 2026

Quanterix (QTRX) Corporation announced plans to debut its Content Innovation Engine at the American Association for Cancer Research, AACR, Annual Meeting 2026. Built on the integration of Akoya Biosci...

4 weeks ago - TheFly

Quanterix Debuts Content Innovation Engine at AACR 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX) today announced plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeti...

4 weeks ago - Business Wire

Quanterix Corporation Announces Date of 2026 Annual Meeting

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the “Company”), today announced that the Co...

6 weeks ago - Business Wire

Quanterix Transcript: Leerink Global Healthcare Conference 2026

New leadership is driving a strategic transformation, emphasizing diagnostics as a growth engine and leveraging the Akoya acquisition for diversification. Financial discipline has resulted in strong recurring revenue and margin recovery, while a differentiated diagnostics test and focused product development position the company for sustainable growth.

2 months ago - Transcripts

Quanterix Transcript: TD Cowen 46th Annual Health Care Conference

Management outlined a strategy focused on diagnostics growth, especially in Alzheimer's, leveraging a strong recurring revenue base and successful Akoya integration. Financial performance exceeded expectations, with robust consumables demand and margin improvements. A comprehensive diagnostics plan and further international expansion are key priorities for future growth.

2 months ago - Transcripts

Quanterix Earnings Call Transcript: Q4 2025

Q4 2025 revenue rose 25% year-over-year to $43.9 million, with strong academic demand and expanded diagnostics partnerships. 2026 guidance targets $169–$174 million revenue, cash flow breakeven in H2, and continued investment in Alzheimer's diagnostics and assay innovation.

2 months ago - Transcripts

Quanterix reports Q4 EPS (49c) vs. (30c) last year

Reports Q4 revenue $43.9M, consensus $38.0M. “I am thrilled to be joining Quanterix (QTRX) at a time when the company is well-positioned to deliver long-term growth,” said Everett Cunningham, Presiden...

2 months ago - TheFly

Quanterix sees FY26 revenue $169M-$174M, consensus $168.8M

Quanterix (QTRX) is issuing its initial guidance for 2026. The Company expects revenues of $169 to $174 million, GAAP gross margin of 45-49%, and adjusted gross margin (non-GAAP) of 49%…

2 months ago - TheFly

Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the f...

2 months ago - Business Wire

Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on...

2 months ago - Business Wire

Quanterix to Participate in Upcoming Investor Conferences

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...

2 months ago - Business Wire

Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...

2 months ago - Business Wire